Three studies including 1629 patients reported the POAF in patients pretreated with rosuvastatin or placebo30,31,38 . Rosuvastatin was correlated to a reduced prevalence of POAF (179/819 [21.9%] versus 192/810 [23.7%]). However, there was no statistically significant difference between the two groups (OR 0.90; 95% CI: 0.71 to 1.14, p-value = 0.38). There was severe heterogeneity observed between the three inherent studies (I2= 70%) (Figure 7 ). If we only consider studies with ≥ 199 patients, the results are similar (OR 0.87; 95% CI: 0.68 to 1.12, p-value = 0.29; I2= 84%)(Figure 8 ).